Johnson & Johnson announces submission to WHO for EUL of investigational single-shot COVID-19 vaccine candidate
On Feb. 19, 2021, Johnson & Johnson announced that Janssen-Cilag had submitted for Emergency Use Listing (EUL) to…
On Feb. 19, 2021, Johnson & Johnson announced that Janssen-Cilag had submitted for Emergency Use Listing (EUL) to…
On Feb. 19, 2021, Luminex announced that it had received $11.3 million in funding from the Biomedical Advanced…
On Feb. 18, 2021, scientists at the University of Oxford announced that the Randomised Evaluation of COVID-19 Therapy…
On Feb. 18, 2021, Novavax and announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to…
On Feb. 17, 2021, Moderna announced that the European Commission had purchased an additional 150 million doses of…
On Feb. 17, 2021, Altimmune announced that the U.S. Food and Drug Administration (FDA) had cleared the Companyls…
On Feb. 17, 2021, BioNTech announced an agreement with the European Commission (EC) to supply an additional 200…
On Feb. 17, 2021, Immunic announced that its lead asset, IMU-838, the company’s selective oral DHODH inhibitor, had…
On Feb. 17, 2021, BioNTech announced results from an in vitro study that provided additional data on the…
On Feb. 16, 2021, Moderna provided a supply update for their COVID-19 Vaccine in the United States, reporting…
On Feb. 16, 2021, Anixa Biosciences announced that animal testing had commenced with two proprietary compounds that have…
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
On Feb. 12, 2021, Moderna announced that the Canadian Government had increased its confirmed order commitment by 4…
On Feb. 11, 2021, Cue Health announced the results of an independent clinical validation study conducted by Mayo…
On Feb. 11, 2021, Moderna announced that the Qatar Ministry of Public Health had issued an emergency use…
On Feb. 11, 2021, Moderna announced that the U.S. government had purchased an additional 100 million doses of…
On Feb. 10, 2021, the United States Department of Agriculture (USDA) National Veterinary Services Laboratories announced confirmation of…
On Feb. 9, 2021, Moderna announced two supply agreements for the COVID-19 Vaccine Moderna: one with the government…
On Feb. 8, 2021, Repligen and Navigo Proteins announced that they have completed the development and initiated the commercial…
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the U.S. Food and…
On Feb. 5, 2021, Oxford University announced that a preprint of ongoing work to assess effectiveness of Oxford’s…
On Feb. 4, 2021, Merck affirmed its position regarding use of ivermectin during the COVID-19 pandemic, and do…
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
On Feb. 3, 2021, Bristol-Myers and The Rockefeller University announced an agreement under which Bristol Myers Squibb was…
On Feb. 3, 2021, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 7.5…
On Feb. 3, 2021, Moderna announced that the Singapore Health Sciences Authority (HSA) had approved the interim authorization…
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…